Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Stock Rockets 17%: More To Come?
Specialty biopharmaceutical firm focusing on developing and commercialising products in therapeutic areas, Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on July 19, 2021 announced that after 2021 Annual shareholders meeting, nominees Howard C. Birndorf, Dennis J. Carlo, Ph.D., David J. Marguglio, Roshawn A. Blunt and Richard C. Williams – have been re-elected to the Board of Directors.
The report by Inspector of Election’s report said that stockholders approved all proposals considered at the Annual Meeting. This included approval on advisory basis for compensation to named executive officers as well as the ratification on advisory basis for appointing registered public accounting firm BDO USA, LLP for 2021. Additionally, the Board expressed gratitude to its stockholders for their support and encouragement.
The Pharmaceutical company is present in a number of therapeutic areas, including opioid overdose, allergy and respiratory and inflammatory disease. The firm’s SYMJEPI(epinephrine) Injection products have been approved by the Food and Drug Administration, USA for usage in emergency treatement of acute allergic reactions includinganaphylaxis.
The company’s naloxone injection product candidate, ZIMHI, that is for treating opiod overdose, is presently under review by the FDA. Adamis is also developing some other products such as treatment for acute respiratory diseases, such as COVID-19 as well as radiation dermatitis.
